Navigation Links
Tianyin To Attend ROTH Fall Conference at Maui, Hawaii From September 1 - September 6
Date:8/30/2010

Tianyin To Attend ROTH Fall Conference at Maui, Hawaii From September 1 -... -- CHENGDU, China, Aug. 30 /PRNewswire-Asia-FirstCall/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Supplementary Medicine, Trade Show News Click to view news release full screen  

Tianyin To Attend ROTH Fall Conference at Maui, Hawaii From September 1 - September 6

 

CHENGDU, China, Aug. 30 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical Co., Inc. (NYSE Amex: TPI), a biopharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics will participate in the Roth Fall Conference from September 1 - September 6 at Grand Wailea Resort Hotel, Maui, Hawaii.

Dr. James Jiayuan Tong, Tianyin's Chief Financial Officer, Chief Business & Development Officer and Director is invited to present in two following panel discussions at the conference.

CFO Essentials -- Updates And Practical Implications For CFOs of U.S.-Listed Chinese Companies

Wednesday, September 1, 2:30 pm - 4:00 pm, Haleakala Ballroom China Social Infrastructure Panel Thursday, September 2, 10:00 am - 10:55 am, Haleakala Ballroom

About Tianyin Pharmaceuticals

Tianyin Pharmaceutical Co., Inc., headquartered at Chengdu, China, is a biopharmaceutical company that specializes in the development, manufacturing, marketing and sale of patented biopharmaceutical medicine, modernized traditional Chinese medicines and branded generics. Tianyin currently manufactures a comprehensive portfolio of 56 products, of which 23 are listed in the national medicine reimbursement list, 7 are included in the essential drug list of China. Tianyin currently has a pipeline of 10 late stage products pending the SFDA approval that target various high incidence healthcare indications. Tianyin has an extensive nationwide distribution network with a sales force of 720 sales representatives out of totaled 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

For more information, please contact: Tianyin Pharmaceutical Co., Inc. James Jiayuan Tong M.D. Ph.D. Chief Financial Officer, Chief Business & Development Officer Director Add: 23rd Floor Unionsun Yangkuo Plaza No 2 Block 3 South Renmin Road Chengdu, 610041 China Tel: +86-28-8551-6696 (Chengdu, China) +86-134-3655-0011 (China) +1-949-350-6999 (U.S.) Email: Dr.Tong@tianyinpharma.com Web: http://www.tianyinpharma.com
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tianyin Promotes its Flagship Product Portfolio at the 45th 2010 National New Special Drugs Trade Fair in July at Beijing
2. Tianyin Pharmaceutical Co., Inc. to Host Third Fiscal Quarter 2010 Results Earnings Conference Call on Wednesday, May 12, 2010 at 9:00 a.m. ET
3. Tianyin to Present at 5th Annual Biomedical Forum by Sino American BioPharmaceutical Association
4. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Ofloxacin and Fleroxacin
5. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products
6. Tianyin Pharmaceutical co., Inc. Announces Record First Quarter 2010 Financial Results
7. Tianyin Pharmaceutical, Co. Announces Cash Dividend to Common Shareholders - Record Date October 30, 2009
8. Mindray to Attend the 2010 American Association for Clinical Chemistry Conference
9. Jiangbo Pharmaceuticals to Attend Global Hunter Securities China Conference
10. Novo Nordisk Announces Resources to Help Support Kids with Diabetes Attending Summer Camp
11. Inverness Medical Innovations to Attend the Jefferies 2010 Global Life Sciences Conference on June 8, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... March 29, 2017  Experts in the field ... devices like  Soberlink Systems  as a model for ... published in early 2017, concluded that remote blood ... managing patient recovery." The findings of ... Addiction Medicine, detail a range of variables that ...
(Date:3/29/2017)... , March 29, 2017  Glenmark Pharmaceuticals, ... for GSP 301, an investigational fixed-dose combination of ... mcg) administered twice-daily as a nasal spray being ... These results are from a recently completed Phase ... GSP 301 combination therapy versus mometasone, olopatadine or ...
(Date:3/29/2017)... 29, 2017 Research and Markets has announced ... report to their offering. ... The global lifestyle drugs market to grow at a ... report, Global Lifestyle Drugs Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
Breaking Medicine Technology:
(Date:3/29/2017)... ... 2017 , ... Based on research from Guardian’s Fourth Annual ... trying to balance both short-term and long-term benefits demands. Are employers struggling ... complexity, companies are finding that the short-term strategies used to control costs, improve ...
(Date:3/29/2017)... Chicago, Illinois (PRWEB) , ... March 29, 2017 ... ... Visio Stencils Device Library for documenting and diagramming network and data center assets ... , NetZoom subscribers can request new equipment shapes for free and download ...
(Date:3/29/2017)... ... , ... Immunotherapy has emerged as one of the most promising options for ... the next revolution in our fight against this complex disease. One of the most ... inhibitors such as PD-1 and PD-L1 inhibitors. , While a few single analyte immunohistochemistry ...
(Date:3/29/2017)... ... ... AvePoint , the Microsoft Cloud expert, is pleased to announce the ... the Riverfront Plaza, 901 East Byrd Street. AvePoint is celebrating with a ribbon-cutting ceremony ... Mayor of Richmond Levar M. Stoney. , Founded in 2001, AvePoint employs more than ...
(Date:3/28/2017)... ... March 28, 2017 , ... India’s Chigurupati Technologies ... directly address the resolution to globally reduce the harmful use of alcohol set ... FDA and TTB approved ingredients that when infused into alcohol, renders the alcohol ...
Breaking Medicine News(10 mins):